Holen Sie sich die Stockscreener-App
0.8201
5.60%
-0.0487
Handel nachbörslich:
.80
-0.02
-2.44%
Schlusskurs vom Vortag:
$0.8687
Offen:
$0.8467
24-Stunden-Volumen:
435.98K
Relative Volume:
0.09
Marktkapitalisierung:
$10.91M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.77M
KGV:
-0.0536
EPS:
-15.2954
Netto-Cashflow:
$-24.23M
1W Leistung:
-21.15%
1M Leistung:
-24.07%
6M Leistung:
-65.25%
1J Leistung:
-84.53%
1-Tages-Spanne:
$0.76
$0.8467
1-Wochen-Bereich:
$0.76
$1.04
52-Wochen-Spanne:
$0.3975
$5.91
Moleculin Biotech Inc Stock (MBRX) Company Profile
Firmenname
Moleculin Biotech Inc
Sektor
Branche
Telefon
713-300-5160
Adresse
5300 MEMORIAL DRIVE, HOUSTON, TX
Vergleichen Sie MBRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
0.8201 | 10.91M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-12 | Herabstufung | Maxim Group | Buy → Hold |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
Moleculin Biotech Inc Aktie (MBRX) Neueste Nachrichten
Moleculin Biotech doses first patient in Phase 3 MIRACLE trial - Yahoo Finance
Moleculin Biotech begins dosing subjects in trial of combination therapy for AML - Yahoo
Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial - GlobeNewswire
Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Moleculin Biotech Begins Phase 3 MIRACLE Trial Dosing - TipRanks
Moleculin Doses First Patient In Pivotal, Adaptive Phase 3 Miracle Trial - MarketScreener
Breakthrough AML Treatment Enters Final Testing Phase: Moleculin Launches Pivotal Trial - Stock Titan
Moleculin, CNS, Global-e, Tenet, Summit: Trending by Analysts - MSN
What is HC Wainwright’s Estimate for MBRX FY2025 Earnings? - Defense World
Roth Capital Issues Optimistic Estimate for MBRX Earnings - Defense World
All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy - MSN
Moleculin Biotech (NASDAQ:MBRX) Rating Increased to Buy at Maxim Group - Defense World
Maxim Group Upgrades Moleculin Biotech (MBRX) - MSN
Moleculin Biotech (NASDAQ:MBRX) Upgraded at StockNews.com - Defense World
Maxim Group Upgrades Moleculin Biotech (LSE:0K2H) - Nasdaq
H.C. Wainwright maintains $8 target on Moleculin Biotech stock By Investing.com - Investing.com Australia
H.C. Wainwright maintains $8 target on Moleculin Biotech stock - Investing.com India
Maxim Upgrades Moleculin Biotech to Buy From Hold, Price Target is $4 - Marketscreener.com
Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2024 Earnings Call Transcript - Insider Monkey
Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: Promising Clinical Trials and ... - Yahoo Finance
Moleculin Biotech (NASDAQ:MBRX) Receives Buy Rating from HC Wainwright - Defense World
Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: P - GuruFocus
Moleculin Biotech Advances Clinical Trials Amid Financial Losses - TipRanks
Earnings call transcript: Moleculin Biotech’s Q1 2025 updates on Anamycin trials By Investing.com - Investing.com South Africa
Earnings call transcript: Moleculin Biotech’s Q1 2025 updates on Anamycin trials - Investing.com
Moleculin Biotech Inc Reports Q4 Earnings: EPS of -$1.28, Revenue at $0 Million, Aligns with Analyst Estimates - GuruFocus
Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Moleculin Biotech Shares Corporate Presentation Update - TipRanks
FDA-Optimized Phase 3 AML Trial: Moleculin Cuts Costs, Expands to Europe - Stock Titan
Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: Promising Clinical Trials and ... By GuruFocus - Investing.com Canada
Moleculin Biotech Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Moleculin Biotech, Inc. SEC 10-K Report - TradingView
Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast - GlobeNewswire
Moleculin Biotech Inc expected to post a loss of $1.28 a shareEarnings Preview - TradingView
Moleculin Biotech (NASDAQ:MBRX) Now Covered by StockNews.com - Defense World
Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference - PR Newswire
5 Major Growth Catalysts: Moleculin Biotech CEO Reveals 2025 Strategic Roadmap - Stock Titan
Moleculin to Present at the 37th Annual ROTH Conference - Quantisnow
Moleculin to Present at the 37th Annual ROTH Conference -March 10, 2025 at 08:46 am EDT - Marketscreener.com
Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds - GuruFocus.com
Soft Tissue Sarcoma Market on Track for Major Expansion by 2032, According to DelveInsight | Moleculin Biotech - openPR
Moleculin Announces Additional Annamycin Patent Allowances to En - GuruFocus.com
Moleculin Biotech Inc Announces Additional Annamycin Patent Allowances To Enhance Global Exclusivity - Marketscreener.com
Moleculin Biotech to be granted new patents for Annamycin - TipRanks
Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity - PR Newswire
What is HC Wainwright’s Forecast for MBRX Q4 Earnings? - Defense World
StockNews.com Initiates Coverage on Moleculin Biotech (NASDAQ:MBRX) - Defense World
Finanzdaten der Moleculin Biotech Inc-Aktie (MBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):